TY - JOUR
T1 - Pharmacological approaches to preventing vascular access failure
AU - Polkinghorne, Kevan R
PY - 2008
Y1 - 2008
N2 - The establishment and maintenance of vascular access in
haemodialysis patients represent a major cause of morbidity
in nephrology units. The native arteriovenous fistula (AVF)
is the vascular access of first choice for haemodialysis with
superior long-term patency, lower costs and infection rates
compared to arteriovenous grafts and central venous catheters.
However, primary failure (failure of the created AVF
to be suitable for dialysis) in AVF is a major problem. While
rates of primary failure are lower for AVG, this access has
unacceptably high overall thrombosis rates compared to
AVF. The objective of this guideline is to review the evidence
for pharmacological interventions aimed at reducing
thrombosis of vascular access for haemodialysis.
AB - The establishment and maintenance of vascular access in
haemodialysis patients represent a major cause of morbidity
in nephrology units. The native arteriovenous fistula (AVF)
is the vascular access of first choice for haemodialysis with
superior long-term patency, lower costs and infection rates
compared to arteriovenous grafts and central venous catheters.
However, primary failure (failure of the created AVF
to be suitable for dialysis) in AVF is a major problem. While
rates of primary failure are lower for AVG, this access has
unacceptably high overall thrombosis rates compared to
AVF. The objective of this guideline is to review the evidence
for pharmacological interventions aimed at reducing
thrombosis of vascular access for haemodialysis.
UR - http://www3.interscience.wiley.com.ezproxy.lib.monash.edu.au/cgi-bin/fulltext/120841250/PDFSTART
U2 - 10.1111/j.1440-1797.2008.00993.x
DO - 10.1111/j.1440-1797.2008.00993.x
M3 - Article
VL - 13
SP - 12
EP - 16
JO - Nephrology
JF - Nephrology
SN - 1320-5358
IS - Suppl 2
ER -